AC Immune backs alpha-synuclein despite recent setbacks
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Eisai and Biogen throw good money after bad
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
Full BAN2401 reveal gives Biogen a reality check
Data on Alzheimer's disease project spoiled by patient exclusions.
AAIC event – Biogen and Eisai move to consolidate beta-amyloid lead
Two weeks ago BAN2401 was hailed as a possible disease-modifying Alzheimer's drug. Full data at the AAIC meeting to will show whether or not this is was all hype.
Biogen rekindles the eternal beta-amyloid flame
Hope anew for the beta-amyloid hypothesis from yet another highly inconclusive Alzheimer's disease trial.
Tide turns as 2017 IPOs ramp up
Biotechs raised $3.9bn in IPOs across 2017, signalling that investor interest in new issues has returned.
